Journal article

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Matteo S Carlino, Shahneen Sandhu

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2017

DOI: 10.1200/JCO.2017.75.2055

Citation metrics

4Web of Science

Keywords

Double-Blind
Life Sciences & Biomedicine
Oncology
Skin Neoplasms
Ipilimumab
Humans
Melanoma
Nivolumab
Science & Technology
Pembrolizumab
Phase-3 Trial
Untreated Melanoma